These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 30755439)

  • 81. Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors.
    Martin D; Fallaha S; Proctor M; Stevenson A; Perrin L; McMillan N; Gabrielli B
    Mol Cancer Ther; 2017 Sep; 16(9):1934-1941. PubMed ID: 28522591
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells.
    Miyake K; Takano N; Kazama H; Kikuchi H; Hiramoto M; Tsukahara K; Miyazawa K
    Int J Oncol; 2022 May; 60(5):. PubMed ID: 35348191
    [No Abstract]   [Full Text] [Related]  

  • 83. Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer.
    Deneka AY; Einarson MB; Bennett J; Nikonova AS; Elmekawy M; Zhou Y; Lee JW; Burtness BA; Golemis EA
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32012873
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
    Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
    Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Mitotic Checkpoints and the Role of WEE1 Inhibition in Head and Neck Squamous Cell Carcinoma.
    Khan SN; Swiecicki PL; Doroshow DB
    Cancer J; 2022 Sep-Oct 01; 28(5):381-386. PubMed ID: 36165727
    [TBL] [Abstract][Full Text] [Related]  

  • 86. VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells.
    Ding XF; Zhou J; Chen G; Wu YL
    Mol Med Rep; 2018 Jul; 18(1):1206-1210. PubMed ID: 29845253
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.
    Park SI; Lin CP; Ren N; Angus SP; Dittmer DP; Foote M; Parton T; Bhatt AP; Fedoriw YD; Roth DP; Cann ML; Johnson GL; Damania B
    Target Oncol; 2019 Oct; 14(5):563-575. PubMed ID: 31429028
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Preferential killing of p53-deficient cancer cells by reversine.
    Jemaà M; Galluzzi L; Kepp O; Boilève A; Lissa D; Senovilla L; Harper F; Pierron G; Berardinelli F; Antoccia A; Castedo M; Vitale I; Kroemer G
    Cell Cycle; 2012 Jun; 11(11):2149-58. PubMed ID: 22592527
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Chemopreventive targeted treatment of head and neck precancer by Wee1 inhibition.
    van Harten AM; de Boer DV; Martens-de Kemp SR; Buijze M; Ganzevles SH; Hunter KD; Leemans CR; van Beusechem VW; Wolthuis RMF; de Menezes RX; Brakenhoff RH
    Sci Rep; 2020 Feb; 10(1):2330. PubMed ID: 32047167
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
    J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
    Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
    Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Therapeutic Rationale to Target Highly Expressed Aurora kinase A Conferring Poor Prognosis in Cholangiocarcinoma.
    Ding X; Huang T; Peng C; Ahn KS; Andersen JB; Lewinska M; Cao Y; Xu G; Chen G; Kong B; Friess H; Shen S; Roberts LR; Wang L; Zou X
    J Cancer; 2020; 11(8):2241-2251. PubMed ID: 32127951
    [No Abstract]   [Full Text] [Related]  

  • 93. Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
    Zullo KM; Guo Y; Cooke L; Jirau-Serrano X; Mangone M; Scotto L; Amengual JE; Mao Y; Nandakumar R; Cremers S; Duong J; Mahadevan D; O'Connor OA
    Clin Cancer Res; 2015 Sep; 21(18):4097-109. PubMed ID: 25878331
    [TBL] [Abstract][Full Text] [Related]  

  • 94. 5-aza-2'-deoxycytidine induces apoptosis and inhibits tumour growth in vivo of FaDu cells, a specific HPVnegative HNSCC cell line.
    Miari R; Azzam N; Bar-Shalom R; Fares F
    PLoS One; 2021; 16(9):e0253756. PubMed ID: 34534222
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
    Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
    Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Therapeutic potential of mitotic interaction between the nucleoporin Tpr and aurora kinase A.
    Kobayashi A; Hashizume C; Dowaki T; Wong RW
    Cell Cycle; 2015; 14(9):1447-58. PubMed ID: 25789545
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
    Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P
    Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.
    Robinson AM; Rathore R; Redlich NJ; Adkins DR; VanArsdale T; Van Tine BA; Michel LS
    Cell Death Dis; 2019 Nov; 10(11):867. PubMed ID: 31727874
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
    Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
    Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
    [TBL] [Abstract][Full Text] [Related]  

  • 100. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
    Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
    Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.